Press Releases

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Prof Dr John F. Stover as Chief Medical Officer.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce today that the Last Patient Last Visit (LPLV) in its phase 3 NOSTRA III clinical trial occurred on June 17, 2020

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.

vasopharm today announced the successful completion of a € 9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments. Existing investors Bayern Kapital, Future Capital, clients of Hanseatic Asset Management and Ringtons Holdings also participated in the round. In addition, vasopharm welcomed Creathor Ventures as new investor and Christian Leikert, Partner at Creathor Ventures, joins vasopharm’s board of directors.

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH, a privately held biopharmaceutical company, today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial. This milestone triggers an interim review by the Data Monitoring Committee (DMC) in line with the agreed study protocol. Allowing for the six month extended Glasgow Outcome Scale (eGOS) evaluation for the 110th eligible patient recruited, the company expect feedback from the DMC in Q4 2018.

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer. In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.